Jaguar Health Reports Q2 2026 Financials

Jaguar Health reports progress on crofelemer for rare intestinal failure, highlighting ESPGHAN 2026 findings showing up to 48% reduction in parenteral nutrition needs in a patient with microvillus inclusion disease and aiming to have an NDA-ready clinical package for MVID by end-2026 with NDA submission in Q2 2027. In Q2 2026, the company posted revenue of about $1.23 million and a net loss of $12.68 million, with Neonorm over-the-counter sales remaining minimal. The company continues to report non-GAAP EBITDA metrics alongside GAAP figures, noting ongoing net losses that management views as signaling the operational foundation for future growth. Jaguar also reaffirmed plans to host an investor webcast on August 19, 2026, to review second-quarter results and corporate updates. The disclosures emphasize the non-GAAP measures for investors, the company’s focus on crofelemers’ development, and the broader context of its quarterly performance. Jaguar’s six-month 2026 results show revenue of about $21.5 million and a net loss of roughly $3.83 million, underscoring a pattern of investment ahead of potential regulatory approvals and commercial milestones.